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Abstract
Background: Chronic refractory angina is a challenging clinical problem with limited treatment options. The results
of early cardiovascular stem cell trials using ABMMC have been promising but have utilized intracoronary or
intramyocardial delivery. The goal of the study was to evaluate the safety and early efficacy of autologous bone
marrow derived mononuclear cells (ABMMC) delivered via percutaneous retrograde coronary sinus perfusion
(PRCSP) to treat chronic refractory angina (CRA).
Methods: From May 2005 to October 2006, 14 patients, age 68 +/- 20 years old, with CRA and ischemic stress-induced
myocardial segments assessed by SPECT received a median 8.19*10
8 ±4 . 3 * 1 0
8 mononuclear and 1.65*10
7 ±1 . 4 2 * 1 0
7
CD34
+ cells by PRCSP..
Results: ABMMC delivery was successful in all patients with no arrhythmias, elevated cardiac enzymes or
complications related to the delivery. All but one patient improved by at least one Canadian Cardiovascular Society
class at 2 year follow-up compared to baseline (p < 0.001). The median baseline area of ischemic myocardium by
SPECT of 38.2% was reduced to 26.5% at one year and 23.5% at two years (p = 0.001). The median rest left
ventricular ejection fraction by SPECT at baseline was 31.2% and improved to 35.5% at 2 year follow up (p = 0.019).
Conclusions: PRCSP should be considered as an alternative method of delivery for cell therapy with the ability to
safely deliver large number of cells regardless of coronary anatomy, valvular disease or myocardial dysfunction. The
clinical improvement in angina, myocardial perfusion and function in this phase 1 study is encouraging and needs
to be confirmed in randomized placebo controlled trials.
Background
An increasing number of patients with coronary artery
disease remain symptomatic with disabling angina
despite the optimal use of antianginal medications and
percutaneous or surgical revascularization [1,2]. Thera-
peutic angiogenesis is an experimental strategy utilizing
angiogenic proteins, gene therapy or stem cells for indu-
cing neovascularization of chronically ischemic myocar-
dium [3,4]. Currently, the majority of clinical studies
investigating autologous bone marrow mononuclear cells
(ABMMC) transplantation as a treatment for ischemic
myocardium have been performed in patients with acute
myocardial infarction using intracoronary delivery [5-11].
In contrast, in patients with refractory ischemia only a
few trials have been published and all have used intra-
myocardial delivery [12-16]. Percutaneous retrograde
coronary sinus perfusion (PRCSP) is a well-established
technique for delivery of cardioplegia solution in cardio-
vascular surgery and for protection against myocardial
ischemia in patients undergoing high risk percutaneous
coronary intervention (PCI) [17-19]. Delivery by PRCSP
has been shown to be a reasonable alternative to intra-
coronary and intramyocardial delivery in preclinical
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proteins, gene therapy and stem cell therapy [20]. The
technique has the potential advantages of safety deliver-
ing a larger number of cells with more homogenious
delivery across the myocardium to patients with refrac-
tory angina despite the presence of severe underlying
coronary artery disease, valvular disease or previous myo-
cardial infarction which may complicate delivery by
either intracoronary or intramyocardial approach. The
aim of the present study was to evaluate the safety of
ABMMC delivered into the ischemic myocardium via
PRCSP in patients with chronic refractory angina (CRA).
Methods
Patients
Patients with Canadian Cardiovascular Society (CCS) class
III-IV angina despite maximal medical or surgical therapy
who were ineligible for further percutaneous or surgical
revascularization (based on coronary anatomy) and who
had evidence for reversible ischemia on an exercise single
photon emission computed tomography (SPECT) were
enrolled. A committee comprising two cardiovascular sur-
geons and two interventional cardiologists determined the
ineligibility for percutaneous or surgical revascularization.
Patients with acute myocardial infarction, percutaneous or
surgical revascularization within six months of enrollment
in the study, a history of malignant disease, severe renal
dysfunction, or unexplained hematology or biochemical
abnormalities were excluded. The local ethics committee
at Clinica Maison de Sante and Centro Cardiovascular San
Nicolá s approved the protocol and all patients gave
informed consent. The review and analysis of the data was
also approved by the IRB at the University of Utah.
Study protocol
The baseline screening assessment of patients included
clinical evaluation, electrocardiogram (ECG), laboratory
evaluation (complete blood count, blood chemistry, ery-
throcyte sedimentation rate, creatine kinase, and troponin
T serum levels). Patients kept a record of daily angina fre-
quency for three weeks, and the severity of angina was
graded according to the CCS class at baseline, 3, 12, and
24 months. Within two weeks prior to cell therapy, exer-
cise capacity was evaluated using bicycle ergometry in
conjunction with SPECT imaging to assess myocardial
ischemia and left ventricular (LV) function.
Periprocedural evaluation
Patients had complete blood count, creatine kinase levels
and ECG performed immediately prior to and immediate
after the procedure. Complete blood count, creatine
kinase, and troponin T levels were also assessed eight
hours post procedure with an ECG prior to discharge. All
patients were monitored in the cardiac intensive care unit
for 12 hours after the procedure and were discharged the
following day. A transthoracic echocardiogram was
performed prior to discharge to detect the presence of
pericardial effusion. The clinical follow-up evaluations
including the laboratory tests described above were per-
formed 3, 12 and 24 months after the injection proce-
dure. At 12 and 24 months of follow-up exercise bicycle
testing, and gated SPECT were performed.
Assessment of exercise capacity
All patients performed a symptom-limited bicycle exercise
test with a 20-W starting load and 10-W increments per
minute at baseline and at 12 and 24 months after the
injection procedure. Antianginal medication was contin-
ued. The test points were angina pectoris, physical exhaus-
tion, dyspnea, significant decrease in blood pressure
(10 mmHg), or achievement of maximal age-related heart
rate. A 12-lead ECG was recorded before, during, and
after the test. The total exercise duration, maximal work-
load achieved in percentages (expected for age, gender,
height, and weigh) at baseline was compared to 12 and
24 months after ABMMC delivery.
Single-photon emission computed tomography
For the SPECT examination, a one-day rest-stress proto-
col was used. On the same day, images at rest were
obtained 60 minutes after the
99 mTechnetium Sestamibi
injection using a double-head SPECT camera as pre-
viously described. (17,18) Using the bicycle exercise test,
99 mTechnetium Sestamibi was injected intravenously at
peak exercise (85% of the estimated heart rate) which
was continued for 2 minutes after tracer injection and
images were obtained 30 minutes after the stress test.
Reconstruction yielded long-and short -axis projections
perpendicular to the heart axis. The short-axis slices
were displayed in polar map format.
Bone marrow aspiration and isolation of mononuclear
cells
A volume of 300 ml of bone marrow was harvested from
the iliac crest under local anesthesia and placed in hepari-
nized Hanks’ balanced salt solution. ABMMC were iso-
lated by Hess 6% density gradient centrifugation with a
final suspension volume of 50 ml and a mean cell concen-
tration of 8.19*10
8 ±4 . 3 * 1 0
8 mononuclear cells and
1.65*10
7 ±1 . 4 2 * 1 0
7 CD34+ cells.
Delivery Procedure
The femoral vein was cannulated with a 7 French sheath, a
6 French catheter was placed in the coronary sinus and a
0.035 mm hydrophilic guide wire was placed in the inter-
ventricular or lateral vein followed by placement of a per-
ipheral balloon into the mid portion of the coronary sinus
to allow nonselective delivery of cells. (Cook Medical,
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sure (1 to 2 atm) for 10 minutes producing stagnation of
t h ef l o wa sp r e v i o u s l yd e s c r ibed with infusion of the
ABMMC.(18,19) 50 mls of ABMMC were injected manu-
ally through the balloon at a rate of 10 mls per minute.
The average total procedure time for cell delivery was
30 minutes.(Figure 1)
Statistical analysis
Data are reported as median ± SDs. Quantitative data
were compared using a paired, 2 tailed Student’st e s t .
Categorical data were compared using the Wilconxon
signed rank test, a p < 0.05 was considered significant.
Results
The baseline clinical characteristics of the 14 enrolled RA
patients are listed in Table 1. All patients had three vessel
disease and were deemed ineligible for further revasculari-
zation by the screening committee of physicians. The
patient’s antianginal regimen was not changed during the
24 month follow-up.
Safety assessment
There was no evidence of inflammation or myocardial
injury based on periprocedural laboratory evaluations
(maximum erythrocyte sedimentation rate 20 ± 12 mm,
maximum creatine kinase 137 ± 68 U/L, and maximum
troponin T 0.010 ± 0.019 ng/mL) Ventricular arrhythmias
were not observed during cell delivery or hospitalization
and no patient had post procedural pericardial effusion by
two-dimensional echocardiography before discharge. One
patient died four months following the procedure due to
liver cirrhosis, decompensated heart failure and pulmonary
hypertension.
Clinical outcomes
The frequency of angina episodes per day decreased
from 2.9 ± 3.9 at baseline to 1.0 ± 1.4 at 3 months (p <
0.001), 0.7 ± 1.2 at 12 months (p < 0.001) and 0.6 ± 1.2
at 24 months (p < 0.001). Angina improved in 13/14
patients and the mean Canadian Cardiovascular Society
class improved from 3.2 ± 0.6 baseline to 1.9 ± 0.7 at 1
year (p < 0.001) and 1.8 ± 0.4 at 2 years (p < 0.001).
The individual changes for anginal episodes per day for
the 14 patients are shown in Figure 2.
Exercise capacity
At baseline, 14 patients had exercise duration time of
3.1 ± 1.4 minutes. This improved to 6.8 ± 1.0 and 7.4 ±
1.7 minutes at 12 and 24 months of follow-up respec-
tively, (p < 0.001). The individual changes for exercise
time are shown in Figure 3.
Myocardial perfusion by SPECT
The median percent of ischemic myocardium by SPECT
was 38.2% at baseline and was reduced to 26.5% and
23.5% (p = 0.001) at 12 and 24 month follow-up (Table 2
and Figure 4). The number of segments with stress-indu-
cible ischemia per patient improved 11.7% and 14.7% at
12 and 24 months of follow up. Examples of SPECT
   
A  B 
Figure 1 A: Unselected transplantation of BMC into the coronary veins, B: Selected transplantation of BMC into the lateral veins.
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ABMMC is shown for 2 patients in Figure 4A and 4B
with improvements in both rest and stress perfusion.
LV Function assessed by SPECT
Median rest LV ejection fraction by SPECT at baseline was
31.2% and was improved to 35.4% and 35.5% at 12 and
24 month follow-up respectively (p < 0.019). (Table 2,
Figure 5)
Discussion
This study demonstrates that ABMMC delivered by
PRCSP in patients with CRA and stress-inducible ische-
mia was safe, may reduce anginal symptoms and
improve exercise capacity. Stem cell transplantation by
PRCSP is an alternative route of delivery to the myocar-
dium for patients with coronary artery occlusion at their
initial portions, or for patients with severe multivessel
disease or occluded venous and arterial grafts. In this
study we have demonstrated that, in patients with
chronic ischemia with or without severely impaired LV
function, that ABMMC injection enhances myocardial
perfusion. In addition we observed that improved systo-
lic LV function occurred only in patients with low ejec-
tion at baseline. Improvement and maintenance of the
LV ejection fraction at 24 months follow-up was most
likely a result of increased myocardial perfusion and global
regional wall motion. This resulted in a reduced LV end-
systolic volume. Consequently, the therapeutic effect
appears to be more related to enhanced myocardial con-
tractility rather than induction of LV reverse remodeling.
The findings of the present study are consistent with the
hypothesis that ABMMC promote angiogenesis, resulting
in increased myocardial perfusion [18]. The present study
was not designed to assess the underlying cellular mechan-
ism of bone marrow cell injection improving myocardial
perfusion and LV function. Therefore, secretion of pro-
angiogenic factors by the bone marrow cells and differen-
tiation of bone marrow cells in endothelium cells, smooth
muscle cells, or cardiomyocytes could have contributed to
the described effect. The mechanism of angiogenesis could
be caused by differentiation of bone marrow cells in
endothelial and/or vascular smooth muscle cells or by
the production of angiogenic cytokines, as previously pro-
posed but has not been fully validated [19]. ABMMC by
the PRCSP has been proposed as a novel therapeutic
option for patients with coronary artery disease. Until now
most clinical studies investigating ABMMC were per-
formed in patients with acute myocardial infarction. Data
from patients with chronic ischemia are scarce. At present,
only few studies in patients with chronic coronary artery
disease have been published [9-13]. The current results
are in line with studies on the safety and feasibility of
intramyocardial delivery of ABMMC in patients with
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Figure 2 Clinical outcomes of angina class.
Table 1 Baseline Clinical Demographics
Demographic ABMMC*
(N = 14)
Median age 68
Female/Male ratio 1/6
Systemic Hypertension - N (%) 14 (100%)
Hyperlipidemia - N (%) 12 (85.7%)
Diabetes Mellitus - N (%) 4 (28.6%)
Previous myocardial infarction - N (%) 14 (100%)
Previous percutaneous coronary intervention - N (%) 4 (28.6%)
Previous coronary artery bypass surgery - N (%) 9 (64.3%)
*ABMMC = autologous bone marrow mononuclear cells
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Figure 3 Exercise Capacity.
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Page 4 of 7Table 2 Analysis pre and post ABMMC transplantation: Canadian Cardiovascular Society class, rest left ventricular
ejection faction and ischemic myocardium percent
BASELINE
(N = 14)
1 YEAR
(N = 13)
2 YEARS
(N = 13)
P value
REST Global LVEF* (%)
Median
31.2 35.4 35.5 0.019
CCS† Median 3 2 2 <0.001
Ischemic Myocardium (%) Median 38.2 26.5 23.5 0.001
*LVEF = left ventricular ejection fraction; †CCS = Canadian Cardiovascular Society
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Figure 4 A: Perfusion imaging in a patient at 2 year follow up, B: Perfusion imaging in another patient at 2 year follow up.
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Page 5 of 7chronic ischemia and angina pectoris. Tse et al
9 described
a reduction in anginal symptoms, improved wall motion
and improved wall thickening at 3 ‘months follow-up in 8
patients. In addition, the area of hypoperfused myocar-
dium was reduced on SPECT. Fuchs et al reported a
reduction in anginal symptoms and improved myocardial
perfusion in 27 patients with a trend toward improved LV
ejection fraction [11]. Perin et al reported the same results
in 21 patients [12]. In a randomized controlled study
Losordo et al demonstrated data that CD34 + after GCSF
can be safely transplanted via intramyocardial injection
and may improve perfusion and reduce symptoms in
patients with advanced coronary disease [14]. In this pilot
trial ABMMC were successfully delivered in each patient
without any major periprocedural events (i.e., death, myo-
cardial infarction, ventricular arrhythmias, cardiac perfora-
tion, pericardial effusion or significant enzyme release)
using PRCSP. The present study supports previously sug-
gested beneficial effects in preclinical models of retrograde
stem cells delivery for cardiac disease,[21,22] and the first
to demonstrate improvement on symptoms, perfusion
defects and LV function by PRVST in patients with pre-
served or decreased LV ejection fraction. However, we
found similar improvements in patients with chronic
ischemia with or without severely impaired LV function.
This study suggests improvement and potential outcome
durability of angina symptoms relief and better angina
class, myocardial perfusion and contractility with this ther-
apeutic approach in chronic refractory angina patients. We
believe there may be clinical potential for this relatively
novel method of cell delivery for patients suffering from
refractory angina. We currently have a number of clinical
trials using retrograde delivery of cells for both chronic
refractory angina and heart failure based on this trial. Lar-
ger randomized trials will be needed to determine optimal
cell numbers and to further understand the clinical
outcomes.
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